ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japanese Pharmacology & Therapeutics (JPT)

Vol. 48 Suppl. 1 2020

■ REVIEW Clinical Trials and Research in Japan: Progress over the Past Decade

Introduction to the Special Feature: the Last Decade, COVID-19, the Next Decade

Y. Ohashi

Jpn Pharmacol Ther 2020; 48 (s1) : s5-6.


A Review of the Past Ten Years and Prospects for Clinical Data Management in Japan

H. Ohtsu

Jpn Pharmacol Ther 2020; 48 (s1) : s7-12.


Quality Control and Quality Assurance in Clinical Trials and Research

T. Yamaguchi

Jpn Pharmacol Ther 2020; 48 (s1) : s13-16.


Environmental Changes of Investigator-initiated Clinical Trials and the 10-year Progress in JCOG

K. Nakamura, et al

Jpn Pharmacol Ther 2020; 48 (s1) : s17-20.


The Last Decade of Challenge in WJOG

K. Takeda

Jpn Pharmacol Ther 2020; 48 (s1) : s21-24.


History of International Regulation―Focusing on GCP Renovation

O. Komiyama

Jpn Pharmacol Ther 2020; 48 (s1) : s25-29.


History of Creation and Development of Medical Innovation System in Academic Research Organizations in Japan
– Pharmaceutical Approval of Regenerative Medicine Products as a Part of Their Achievements

K. Kono, et al

Jpn Pharmacol Ther 2020; 48 (s1) : s30-38.

■ ORIGINAL ARTICLE

Development of RACI Charts for Involvement of Pharmaceutical Companies in Clinical Trials under the Clinical Trials Act

M. Mori, et al

Jpn Pharmacol Ther 2020; 48 (s1) : s39-56.

■ BRIEF REPORTS

Clarification of Problems in Supporting Clinical Research

R. Katashima, et al

Jpn Pharmacol Ther 2020; 48 (s1) : s57-64.


Development of the Core Competency Model for Program and Project Manager Defined by Clinical Trials Act in Japan

K. Iwasaki, et al

Jpn Pharmacol Ther 2020; 48 (s1) : s65-80.